Motixafortide: Dosing Protocols
Dosing guidelines, reconstitution, and administration information
๐TL;DR
- โข1 dosing protocols documented
- โขReconstitution instructions included
- โขStorage: Store vials at 2-8 degrees C (36-46 degrees F). Protect from light. Store in original carton. Reconstituted solution may be stored at room temperature (20-25 degrees C) for up to 4 hours.
Protocol Quick-Reference
Hematopoietic stem cell mobilization for autologous transplantation in multiple myeloma
Dosing
Amount
1.25 mg/kg actual body weight
Frequency
Once per apheresis session
Duration
1-3 doses over mobilization period
Administration
Route
SCSchedule
Once per apheresis session
Timing
Administer 10-14 hours prior to each planned apheresis session; given in conjunction with G-CSF priming (4-5 days prior)
Cycle
Duration
3-7 days (mobilization period)
Repeatable
Single cycle
โ๏ธ Suggested Bloodwork (3 tests)
CBC with differential and CD34+ cell count
When: Baseline
Why: Baseline blood counts and stem cell levels
CD34+ cell count
When: Day of apheresis
Why: Assess adequacy of stem cell mobilization
CBC with differential
When: Post-apheresis
Why: Monitor blood counts after collection
๐ก Key Considerations
- โFDA-approved prescription medication: must be administered in healthcare settings equipped for anaphylaxis management
- โRequired premedication: H1 blocker, H2 blocker, leukotriene inhibitor, and acetaminophen before each dose
- โReconstituted solution must be used within 4 hours
Unlock dosing protocols
Free access to research-backed dosing information for all peptides.
150+ peptide profiles ยท 30+ comparisons ยท 18 research tools
| Purpose | Dose | Frequency | Duration | Notes |
|---|---|---|---|---|
| Stem Cell Mobilization for ASCT in Multiple Myeloma (FDA-Approved) | 1.25 mg/kg actual body weight by subcutaneous injection, administered 10-14 hours prior to initiation of apheresis. | Once per apheresis session. A second dose may be given 10-14 hours prior to a third apheresis if needed. | Used in conjunction with filgrastim (G-CSF) mobilization. G-CSF is administered for 4-5 days prior to apheresis. Motixafortide is given on the evening before each apheresis day. | Must be administered in a healthcare setting equipped to manage anaphylaxis. Premedication with H1 blocker, H2 blocker, leukotriene inhibitor, and acetaminophen is required. |
Unlock full dosage protocols
Free access to complete dosing tables and protocol details.
150+ peptide profiles ยท 30+ comparisons ยท 18 research tools
๐Reconstitution Instructions
Each vial is reconstituted with 2 mL of 0.45% Sodium Chloride Injection, USP at room temperature (20-25 degrees C), resulting in a concentration of 36.5 mg/mL. Up to 1.7 mL (62 mg) can be withdrawn from each reconstituted vial. Reconstituted solution should be used within 4 hours.
Recommended Injection Sites
- โSubcutaneous injection. Administered by a healthcare provider in a clinical setting equipped for anaphylaxis management.
๐งStorage Requirements
Store vials at 2-8 degrees C (36-46 degrees F). Protect from light. Store in original carton. Reconstituted solution may be stored at room temperature (20-25 degrees C) for up to 4 hours.
Community Dosing Protocols
Compare these clinical doses with what community members report using.
0View community protocolsResearch Tools
Before You Begin
Review safety warnings and contraindications before starting any protocol.
Prescribing Information#
Motixafortide (APHEXDA) is an FDA-approved prescription medication. It must be administered by a healthcare provider in a clinical setting equipped to manage anaphylaxis and serious hypersensitivity reactions.
Approved Dosing#
Mobilization Protocol#
| Step | Details |
|---|---|
| G-CSF priming | Filgrastim 10 mcg/kg SC daily for 4 days |
| Day 4 evening | Motixafortide 1.25 mg/kg SC (10-14 hours before apheresis) |
| Day 5 morning | First apheresis session |
| Day 5 evening | Second motixafortide dose if needed (10-14 hours before apheresis) |
| Day 6 morning | Second apheresis session |
| Day 6 evening | Third motixafortide dose if needed (10-14 hours before apheresis) |
| Day 7 morning | Third apheresis session (if needed) |
Dose Calculation#
The dose is based on actual body weight:
- Dose: 1.25 mg/kg actual body weight
- Route: Subcutaneous injection
- Timing: 10-14 hours before each planned apheresis session
Required Premedication#
Before each motixafortide dose, patients must receive:
| Premedication | Purpose |
|---|---|
| H1 receptor antagonist (e.g., diphenhydramine) | Prevent allergic reaction |
| H2 receptor antagonist (e.g., famotidine) | Prevent allergic reaction |
| Leukotriene receptor antagonist (e.g., montelukast) | Prevent allergic reaction |
| Acetaminophen | Manage injection site reactions |
Reconstitution#
- Allow the vial to reach room temperature (20-25 degrees C)
- Reconstitute with 2 mL of 0.45% Sodium Chloride Injection, USP
- Swirl gently until fully dissolved (do not shake)
- Resulting concentration: 36.5 mg/mL
- Withdraw the calculated dose volume
- Use within 4 hours of reconstitution
Target Collection Goals#
The mobilization goal is collection of at least 6 x 10^6 CD34+ cells per kg body weight, which provides adequate stem cells for autologous transplantation and potential backup grafts.
In the GENESIS trial:
- 92.5% of patients achieved this goal within 2 apheresis sessions with motixafortide + G-CSF
- 26.2% achieved this goal with G-CSF alone
Dosing Context#
Motixafortide belongs to the Immune category of research peptides. Dosing protocols for Motixafortide are derived from available clinical trial data. These protocols are provided for research reference only and do not constitute medical advice. Actual dosing decisions should be made by qualified healthcare providers based on individual patient factors.
Research Protocols#
The following dosing protocols have been documented in clinical research for Motixafortide:
Stem Cell Mobilization for ASCT in Multiple Myeloma (FDA-Approved)#
Dose: 1.25 mg/kg actual body weight by subcutaneous injection, administered 10-14 hours prior to initiation of apheresis.
Frequency: Once per apheresis session. A second dose may be given 10-14 hours prior to a third apheresis if needed.
Duration: Used in conjunction with filgrastim (G-CSF) mobilization. G-CSF is administered for 4-5 days prior to apheresis. Motixafortide is given on the evening before each apheresis day.
Must be administered in a healthcare setting equipped to manage anaphylaxis. Premedication with H1 blocker, H2 blocker, leukotriene inhibitor, and acetaminophen is required.
Reconstitution and Preparation#
Each vial is reconstituted with 2 mL of 0.45% Sodium Chloride Injection, USP at room temperature (20-25 degrees C), resulting in a concentration of 36.5 mg/mL. Up to 1.7 mL (62 mg) can be withdrawn from each reconstituted vial. Reconstituted solution should be used within 4 hours.
Injection Sites#
Recommended injection sites for Motixafortide include:
- Subcutaneous injection. Administered by a healthcare provider in a clinical setting equipped for anaphylaxis management.
Site rotation is recommended to minimize local tissue reactions and ensure consistent absorption.
Storage Requirements#
Store vials at 2-8 degrees C (36-46 degrees F). Protect from light. Store in original carton. Reconstituted solution may be stored at room temperature (20-25 degrees C) for up to 4 hours.
Related Reading#
Subscribe to see vendor options
Free access to verified vendor scores, pricing, and suppliers.
150+ peptide profiles ยท 30+ comparisons ยท 18 research tools
Protocol updates
Get notified when we update dosing protocols or publish related comparisons.
Frequently Asked Questions About Motixafortide
Explore Further
Medical Disclaimer
This website is for educational and informational purposes only. The information provided is not intended to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare professional before using any peptide or supplement.